Prior Donepezil 5mg + Prior Donzepezil 10mg + Prior Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Parkinson's Disease
Conditions
Parkinson's Disease, Dementia
Trial Timeline
Mar 1, 2003 → Jul 1, 2006
NCT ID
NCT01327859About Prior Donepezil 5mg + Prior Donzepezil 10mg + Prior Placebo
Prior Donepezil 5mg + Prior Donzepezil 10mg + Prior Placebo is a phase 3 stage product being developed by Eisai for Parkinson's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01327859. Target conditions include Parkinson's Disease, Dementia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01327859 | Phase 3 | Completed |
Competing Products
20 competing products in Parkinson's Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| UB-312 + Placebo | Vaxxinity | Phase 1 | 25 |
| NAV5001 + DaTscan | Navidea Biopharmaceuticals | Phase 3 | 69 |
| piclozotan + 0.9% sodium chloride (normal saline) | Daiichi Sankyo | Phase 2 | 52 |
| E2007 | Eisai | Phase 3 | 77 |
| ARICEPT | Eisai | Phase 3 | 77 |
| Perampanel | Eisai | Phase 3 | 77 |
| GPI 1485 | Eisai | Phase 2 | 52 |
| E2007 | Eisai | Phase 3 | 77 |
| perampanel + placebo | Eisai | Phase 2 | 52 |
| Lemborexant + placebo | Eisai | Approved | 85 |
| Placebo + E2007 + E2007 | Eisai | Phase 3 | 77 |
| E2007 + E2007 + E2007 | Eisai | Phase 2 | 52 |
| E2007 | Eisai | Phase 2 | 52 |
| E2007 | Eisai | Phase 2 | 52 |
| E2007 | Eisai | Phase 2 | 52 |
| 2 mg perampanel + 4 mg perampanel + placebo comparator | Eisai | Phase 3 | 77 |
| Istradefylline (KW-6002) | Kyowa Kirin | Phase 2 | 52 |
| Istradefylline 20 mg or 40 mg | Kyowa Kirin | Phase 3 | 77 |
| Istradefylline (KW-6002) | Kyowa Kirin | Phase 3 | 77 |
| Perampanel | Eisai | Phase 2 | 52 |